Hepatocellular carcinoma (HCC) is a complex cancer that generally arises in the context of cirrhosis. Patients with HCC have symptom burden and impact on health-related quality of life (HRQOL) resulting from underlying liver disease, HCC, and cancer treatments. Patient-reported outcome (PRO) measures may improve the management of patients with HCC by accurately capturing the patient perspective, informing prognosis, guiding treatment decisions, and supporting symptom based and palliative care. Furthermore, PRO use in HCC research could enhance patient-focused therapy development. This review focuses on the clinical and research assessment of PROs among patients with HCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891488 | PMC |
| http://dx.doi.org/10.2147/JHC.S347929 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Hepatocellular Carcinoma Screening: A Comparative Simulated Abbreviated MRI Protocol Study.
Cureus
February 2025
Department of Radiology, Krishna Institute of Medical Sciences, Secunderabad, IND.
Background Patients with risk factors such as viral hepatitis-induced liver cirrhosis, advanced-stage primary biliary cirrhosis, hereditary hemochromatosis, metabolic-associated fatty liver disease, and alcoholic liver disease are more likely to develop hepatocellular carcinoma (HCC). Most HCC patients have advanced-stage disease unresponsive to treatment. Therefore, avoiding or treating viral infections and early detection through routine surveillance, such as repeated liver ultrasonography, are the most effective ways to reduce HCC-related mortality.
View Article and Find Full Text PDFThe Diagnostic Performance of AFP, AFP-L3, DCP, CA199, and Their Combination for Primary Liver Cancer.
J Hepatocell Carcinoma
March 2025
Department of Laboratory Medicine, Huadong Hospital, Fudan University, Shanghai, People's Republic of China.
Purpose: The prevalence of primary liver cancer (PLC) is rising, yet strategies for its early diagnosis remain inadequate. This study aims to identify novel biomarkers to improve the diagnostic ability of PLC.
Patients And Methods: This study included 94 patients with PLC, 128 patients with benign liver disease (BLD), and 79 normal controls (NC) were included.
Improving Health-Related Quality of Life in Hepatocellular Carcinoma Patients: Key Methodologies for Assessing Patient Reported Outcomes and Intervention Targets.
J Hepatocell Carcinoma
March 2025
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Hepatocellular carcinoma (HCC) is a complex cancer that generally arises in the context of cirrhosis. Patients with HCC have symptom burden and impact on health-related quality of life (HRQOL) resulting from underlying liver disease, HCC, and cancer treatments. Patient-reported outcome (PRO) measures may improve the management of patients with HCC by accurately capturing the patient perspective, informing prognosis, guiding treatment decisions, and supporting symptom based and palliative care.
View Article and Find Full Text PDFSLC25A35 enhances fatty acid oxidation and mitochondrial biogenesis to promote the carcinogenesis and progression of hepatocellular carcinoma by upregulating PGC-1α.
Cell Commun Signal
March 2025
Department of Hepatobiliary Surgery, Xijing Hospital, Air Force Medical University, 15 Changle Western Road, Xi'an, Shaanxi, 710032, China.
Mitochondria dysfunction has been closely linked to a wide spectrum of human cancers, whereas the molecular basis has yet to be fully understood. SLC25A35 belongs to the SLC25 family of mitochondrial carrier proteins. However, the role of SLC25A35 in mitochondrial metabolism reprogramming, development and progression in human cancers remains unclear.
View Article and Find Full Text PDFTumor protein 53 gene polymorphism, demographic attributes and associated risk factors among liver cancer patients in Calabar, Nigeria.
BMC Cancer
March 2025
Department of Guidance and Counseling, Faculty of Education, University of Calabar, Calabar, Nigeria.
Mutations in the TP53 gene had been attributed to the development of liver cancer. Hepatocellular carcinoma (HCC) and liver tumour are liver diseases having high mortality rates in several populations. There is no information on the TP53 gene polymorphism among liver diseases patients in Calabar, Nigeria.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!